Celgene Loses Bid To Stay Claims In Thalomid Suit

Law360, New York (June 13, 2008, 12:00 AM EDT) -- A federal court refused Friday to stay Barr Laboratories Inc.'s antitrust cross-claims against Celgene Corp. in order to focus first on the patent issues arising from Celgene's suit to block Barr’s proposed generic version of the cancer drug Thalomid.

Judge Susan D. Wigenton of the U.S. District Court for the District of New Jersey denied Celgene’s motion to bifurcate and stay discovery of Barr’s antitrust and unfair competition counterclaims.

Summit, N.J.-based Celgene filed an amended complaint assserting eight Thalomid patents against Pomona, N.Y.-based Barr, and Barr...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.